Milestone Scientific (NYSEAMERICAN:MLSS) Stock Rating Upgraded by Zacks Investment Research

Milestone Scientific (NYSEAMERICAN:MLSS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, reports. The firm currently has a $2.50 price target on the medical instruments supplier’s stock. Zacks Investment Research‘s price target suggests a potential upside of 14.16% from the company’s previous close.

According to Zacks, “Milestone Scientific, Inc. develops, manufactures, markets and sells equipment and related disposable or consumable items and other products for use primarily by the dental practitioner. The company’s principal product is The Wand(TM), a computer controlled painless injection system enabling the practitioner to more quickly and effectively anesthetize patients in certain dental applications. The company also markets and sells: SplatrFree(TM) disposable prophy angles and related consumable products; and clinically oriented dental products. “

Shares of MLSS opened at $2.19 on Wednesday. Milestone Scientific has a 52 week low of $1.30 and a 52 week high of $4.85. The company has a market cap of $146.19 million, a PE ratio of -21.90 and a beta of 1.32. The firm has a fifty day moving average price of $1.78.

Milestone Scientific (NYSEAMERICAN:MLSS) last announced its quarterly earnings results on Monday, May 17th. The medical instruments supplier reported ($0.01) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.02. Milestone Scientific had a negative return on equity of 39.49% and a negative net margin of 123.64%. On average, research analysts predict that Milestone Scientific will post -0.12 EPS for the current year.

Large investors have recently made changes to their positions in the stock. Credit Suisse AG bought a new position in Milestone Scientific during the 4th quarter worth $27,000. Dock Street Asset Management Inc. bought a new position in Milestone Scientific during the 1st quarter worth $43,000. Bard Financial Services Inc. bought a new position in Milestone Scientific during the 4th quarter worth $53,000. Rhumbline Advisers raised its position in Milestone Scientific by 22.3% during the 4th quarter. Rhumbline Advisers now owns 29,106 shares of the medical instruments supplier’s stock worth $62,000 after purchasing an additional 5,302 shares during the last quarter. Finally, Occudo Quantitative Strategies LP bought a new position in Milestone Scientific during the 1st quarter worth $70,000. 15.54% of the stock is owned by institutional investors and hedge funds.

Milestone Scientific Company Profile

Milestone Scientific, Inc develops computer-controlled anesthetic delivery devices for the medical and dental markets in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent System that are used to control the flow rate of the anesthesia during the injection, which allows virtually painless injections for various dental procedures, including routine fillings, implants, root canals, and crowns.

Recommended Story: If I purchase shares through a brokerage account, am I the holder of record?

Get a free copy of the Zacks research report on Milestone Scientific (MLSS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Milestone Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Scientific and related companies with's FREE daily email newsletter.